EphA3 CAR T cells are effective against glioblastoma in preclinical models

Overview
The study investigates EphA3-targeted CAR T cells for glioblastoma. T cells were transduced and expanded in G-Rex® 24 well plates.
What this paper found
T cells engineered with a new EphA3-targeted chimeric antigen receptor killed EphA3-positive glioblastoma cells and cleared tumors in mouse models. The receptor was built from a novel monoclonal antibody, clone 3C3-1, which detected EphA3 in 35 of 49 glioblastoma biopsies. CAR T cells made from healthy donor blood lysed EphA3-positive U251 cells but not EphA3-negative U87 cells. In mice carrying intracranial U251 tumors, two intravenous infusions blocked tumor growth, and benefit lasted beyond 100 days. The cells also killed patient-derived glioblastoma cultures and neurospheres, and infiltrated patient-derived organoids, where they induced apoptosis in proportion to EphA3 levels.
Note: Preclinical study in cell lines, patient-derived cultures, organoids and immunodeficient mice; the authors note that the approach does not give a complete picture of T-cell trafficking through other organs.
Our preclinical studies show that adoptive transfer of EphA3 CAR T cells in tumor-bearing immunodeficient animals can proliferate, and traverse the mouse blood-brain-barrier and penetrate and eliminate the U251 xenografts within the mouse brain. — Paulo Martins, Rochelle C J D’Souza, Niclas Skarne, Lea Lekieffre, Shane Horsefield, Madusha Ranjankumar, Xiang Li, Thuy T Le, Fiona Smith, Corey Smith, Jacqueline Burrows, Bryan W Day, Rajiv Khanna, Journal for ImmunoTherapy of Cancer
Study details
- Authors
- Paulo Martins, Rochelle C J D’Souza, Niclas Skarne, Lea Lekieffre, Shane Horsefield, Madusha Ranjankumar, Xiang Li, Thuy T Le, Fiona Smith, Corey Smith, Jacqueline Burrows, Bryan W Day, Rajiv Khanna
- Institution
- QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia · The University of Queensland, Brisbane, Queensland, Australia · Sid Faithfull Brain Cancer Laboratory, Brisbane, Queensland, Australia
- Journal
- Journal for ImmunoTherapy of Cancer
- Year
- 2024
- G-Rex® model(s)
- G-Rex®24 Well Plate
- Cell type(s)
- CAR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
EphA3 CAR T cells were generated in G-Rex® 24-well plates. PBMCs from healthy donors were stimulated with T-cell TransAct and transduced with EphA3 CAR lentivirus (MOI 20) at 1 × 10^6 cells/cm2 in 500 µL transduction medium containing 10% FCS, 300 IU recombinant IL-2 and 1× LentiBOOST. Cultures were then maintained at 37°C and 5% CO2 in medium with 120 IU IL-2 and expanded for 14 days, or sorted on days 7-10 and cultured to day 17. The expanded cells were used for in vitro killing assays and mouse xenograft studies.
Explore related
Full citation
Martins P, D'Souza RCJ, Skarne N, et al. EphA3 CAR T cells are effective against glioblastoma in preclinical models. J Immunother Cancer. 2024;12(8):e009403.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.